Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LM-24C5

Phase 2Small molecule

LLaNova Medicines Limited

LM-24C5 is one of 83 small molecule programs targeting Phase II. It is currently in Phase 2.

2

Indications

2

Total Trials

2

Active Trials

82

Competitors

Pipeline

Status by Indication[3][1]

Indication

Phase IIRecruiting

Advanced Solid TumorsRecruiting

Phase IIPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Taxol

Opdivo

Bristol-Myers Squibb

Fludara

Avastin

Paraplatin

Tecentriq

Imfinzi

Taxotere

Cytoxan

BBaxter Healthcare Corporation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Advanced Solid Tumors

NCT06187402

Q4 2028

Phase 2Recruiting

Phase II

NCT07387081

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

A Study of LM-24C5 For Advanced Solid Tumors

Recruiting·LLaNova Medicines Limited·Phase 1/2·NCT06187402·49 enrolled

Phase II1 trial

Phase II Study of LM-24C5

Recruiting·LLaNova Medicines Limited·Phase 2·NCT07387081·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LM-24C5. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LM-24C5 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LM-24C5. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LaNova Medicines Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLaNova Medicines Limited

Related News